Increased expression of endosomal members of toll-like receptor family abrogates wound healing in patients with type 2 diabetes mellitus

International Wound Journal

Volumn 13, Issue 5, 2016, Pages 927-935

  Singh, Kanhaiya ^a   Agrawal, Neeraj K ^b   Gupta, Sanjeev K ^b   Mohan, Gyanendra ^c   Chaturvedi, Sunanda ^c   Singh, Kiran ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c Indian Railways Cancer Inst Res C   (India)

Author keywords

Diabetic foot ulcer; T2DM; TLR7; TLR9; Toll like receptors; Wound healing impairment

Indexed keywords

MESSENGER RNA; TLR7 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ADULT; AGED; CASE CONTROL STUDY; COMPLICATION; DIABETIC FOOT; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; WOUND HEALING;

ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; WOUND HEALING;

EID: 84922760316     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/iwj.12411     Document Type: Article

References (40)

1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1998;341:738–46.
2. Calvin M. Cutaneous wound repair. Wounds 1998;10:12–32.
3. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835–70.
4. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361: 1545–51.
5. Zhang Z, Schluesener HJ. Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci 2006;63: 2901–7.
6. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004;4:499–511.
7. Stefan K, Drexler SK. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010;42:506–18.
8. Alzabin S, Kong P, Medghalchi M, Palfreeman A, Williams R, Sacre S. Investigation of the role of endosomal toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther 2012;14:R142.
9. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190e8.
10. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, Barton GM. The ectodomain of toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008;456:658–62.
11. Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, Barrat FJ. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. JExpMed2010;207:2931–42.
12. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia–reperfusion injury. Hepatology 2010;51:621–32.
13. Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J 2004;18:412–4.13.
14. Singh K, Agrawal NK, Gupta SK, Singh K. A functional SNP-1562C > T in the matrix metalloproteinases-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds 2013;12:199–204.
15. Dasu MR, Ramirez S, Isseroff RR. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci 2012;22:203–14.
16. Kanhaiya S, Agrawal NK, Gupta SK, Singh K. Differential expression of toll like receptor 4 in type 2 diabetic patients with impaired wound healing. J Diabetes Metab 2013;4:260.
17. Singh K, Singh VK, Agrawal NK, Gupta SK, Singh K. Association of toll-like receptor 4 polymorphisms with diabetic foot ulcers and application of artificial neural network in DFU risk assessment in type 2 diabetes patients. Biomed Res Int 2013;2013:318686.
18. Singh K, Singh VK, Agrawal NK, Gupta SK, Singh K. Genetic alterations in toll-like receptor 4 signaling pathway and impairment of wound healing in patients with type 2 diabetes. Int J Low Extrem Wounds 2014;13:162–3.
19. Falck-Hansen M, Kassiteridi C, Monaco C. Toll-like receptors in atherosclerosis. IntJMolSci2013;14:14008–23.
20. Wagner FW. The dysvascular foot: a system of diagnosis and treatment. Foot Ankle 1981;2:64–122.
21. Patni S, Wynen LP, Seager AL, Morgan G, White JO, Thornton CA. Expression and activity of toll-like receptors 1–9 in the human term placenta and changes associated with labor at term. Biol Reprod 2009;80:243–8.
22. Souil E, Capon A, Mordon S, Dinh-Xuan AT, Polla BS, Bachelet M. Treatment with 815-nm diode laser induces long-lasting expression of 72-kDa heat shock protein in normal rat skin. Br J Dermatol 2001;144:260–6.
23. Hirabara SM, Gorjao R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol 2012;2012: 379024.
24. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010;2010:672395.
25. Reiber GE. The epidemiology of diabetic foot problems. Diabetes Med 1996;13(S1):S6–11.
26. Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabetes Med 2006;23:594–608.
27. Guo S, DiPietro LA. Factors affecting wound healing. J Dent Res 2010;89:219–29.
28. Goova M, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of RAGE restores effective wound healing in diabetic mice. Am J Pathol 2001;159:513–25.
29. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. JMolMed2009;87:125–38.
30. McKelvey KJ, Highton J, Hessian PA. Cell-specific expression of TLR9 isoforms in inflammation. J Autoimmun 2011;36:76–86.
31. Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, Flavell RA, Wong FS, Wen L. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol 2009;183:3712–9.
32. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007;25:419–41.
33. Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, Grigg ME, Berzofsky JA, Belkaid Y. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29:637–49.
34. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, Barrat FJ. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005;174:5193–200.
35. Walker WE, Booth CJ, Goldstein DR. TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome: DNA. Mol Ther 2010;18:775–84.
36. Zhang Y, Lee AS, Shameli A, Geng X, Finegood D, Santamaria P, Dutz JP. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J Immunol 2010;184:5645–53.
37. Liu HY, Hong YF, Huang CM, Chen CY, Huang TN, Hsueh YP. TLR7 negatively regulates dendrite outgrowth through the Myd88–c-Fos–IL-6 pathway. JNeurosci 2013;33:11479–93.
38. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783–801.
39. Pradhan L, Andersen ND, LoGerfo FW, Veves A. Molecular targets for promoting wound healing in diabetes. Recent Pat Endocr Metab Immune Drug Discov 2007;1:1–13.
40. Dasu MR, Isseroff RR. Toll-like receptors in wound healing: location, accessibility, and timing. J Invest Dermatol 2012;132:1955–8.